



**Synthesis of Chiral Spiro 3-Oxazolin-5-one 3-Oxides (Chiral Nitrones)  
via a Nitrosoketene Intermediate  
and Their Asymmetric 1,3-Dipolar Cycloaddition Reactions  
Leading to the EPC Synthesis of Modified Amino Acids.**

**Nobuya Katagiri,\* Makoto Okada, Yoshihiro Morishita, and Chikara Kaneko**


*Pharmaceutical Institute, Tohoku University, Aobayama, Aoba-ku, Sendai 980-77, Japan*

**Abstract:** Cycloaddition of chiral cyclic ketones such as (-)-menthone, (+)-nopinone, and (+)-camphenilone to nitrosoketene generated by thermolysis of 5-hydroxyimino-2,2-dimethyl-1,3-dioxane-4,6-dione gave the corresponding chiral spiro 3-oxazolin-5-one 3-oxides (chiral cyclic nitrones). These nitrones underwent asymmetric 1,3-dipolar cycloaddition reactions with electron rich olefins to give the corresponding oxazolidine derivatives with high diastereoselectivity, which were converted to optically pure amino acids. © 1997 Elsevier Science Ltd.

## Introduction

Recently, Tidwell and coworkers have calculated at the HF/ 6-31G\*\*/ HF- 6-31G\* level the structure and energy of nitrosoketene (**2**) and have predicted that the ketene will have reasonable thermodynamic stability, although it might be quite reactive in a kinetic sense.<sup>1,2</sup> However, although numerous papers dealt with the chemistry of ketene intermediates,<sup>3</sup> none describes the reaction involving **2** as a reactive intermediate, and the detection of **2** by spectroscopy. Quite recently, we have reported a new synthesis of cyclic nitrones **B** (3-oxazolin-5-one 3-oxides) from the reaction of 5-hydroxyimino-2,2-dimethyl-1,3-dioxane-4,6-dione (**1**: isonitroso Meldrum's acid) with ketones. This reaction can be considered to involve the cycloaddition of ketones with **2** generated by thermolysis of **1**, and there are two pathways for the formation of **B**: one is that the *cisoid* nitrosoketene initially undergoes [4+2] cycloaddition with ketones to form the dioxazines **A** which are then transformed to the nitrones **B**; another is that the *transoid* nitrosoketene directly undergoes [3+2] cycloaddition with ketones to give the nitrones **B**.<sup>5,6</sup> Later, Birney and his coworker were interested in our reaction, and proposed using the *ab initio* calculation of the energy on [4+2] or [3+2] transition state that the reaction proceeded with [3+2] cycloaddition to form the cyclic nitrones **B**.<sup>7</sup>

As an extension of our nitrosoketene chemistry, we report here the synthesis of chiral spiro nitrones *via* **2** and their asymmetric 1,3-dipolar cycloaddition reactions leading to the EPC (enantiomerically pure compound) synthesis of amino acids.<sup>8</sup> A part of this work has already appeared as communications.<sup>9,10</sup>




Scheme 1

## Results and Discussion

### Synthesis of Chiral Spiro 3-Oxazolin-5-one 3-Oxides


According to the reaction conditions previously reported in the synthesis of achiral cyclic nitrones,<sup>6</sup> (-)-menthone (**3**) was heated with **1** in toluene to give two nitrones **4** and **5** in 26% and 28% yields,<sup>11</sup> respectively, which were chromatographically separable from each other. Since the structure of the less polar nitrone **4** was determined to be *5R* by X-ray crystallographic analysis,<sup>9</sup> the structure of more polar nitrone **5** coincided with the configuration of *5S*. In a similar manner, (+)-nopinone (**6**) and (+)-camphenilone (**8**) also reacted with **1** to form chiral nitrones **7** and **9** as sole products in 62% and 51% yields, respectively. In these reactions, the corresponding diastereomers **7'** and **9'** were not detected. The structure of **7** was again determined to be *5R* by X-ray crystallographic analysis.<sup>5</sup> The reaction of **3** with **2** produced two isomers because both attack-sides of **2** to the carbonyl group of **3** would be sterically equal. On the contrary, only compound **7** was formed by the attack of **2** from the less hindered side of **6** as shown in Scheme 2. In a similar fashion, **2** approached from the less hindered side (convex face) of **8** to form **9** exclusively. Therefore, the structure of **9** should be the *5S* configuration.



Scheme 2


**Asymmetric 1,3-Dipolar Cycloaddition Reactions of Chiral Nitrones to Electron Rich Olefins and Conversion of Their Adducts to Enantiomerically Pure Amino Acids.**

Previously, we reported the 1,3-dipolar cycloaddition of ethyl vinyl ether or allyltrimethylsilane with the achiral nitron (10) obtained from the reaction of 1 with cyclohexanone to give the *endo* adduct C exclusively.<sup>6</sup> This is because the product D derived from C by LiAlH<sub>4</sub> reduction was assigned to be 3,5-*cis* by the NOE experiment as shown in Scheme 3.<sup>12</sup> We reinvestigated the reaction and concluded on the basis of the NOE experiment of the adducts 11a,b themselves that the products were not the *endo* adducts C but the *exo* adducts 11a,b. Though the adducts 11a,b could not be purified by silica gel column chromatography as reported previously, the NOE experiments of both crude compounds 11a,b revealed that the adducts 11a,b definitely were the *exo* adducts.<sup>14</sup> Thus, as shown in Scheme 3, the NOE effect between 7-H<sub>b</sub> and 7a-H or 6-H and 7-H<sub>a</sub> of 11a,b was observed showing the *exo* adduct. Therefore, the isoxazolidine derivatives (±)-12b obtained by mild alkaline hydrolysis of 11b should be 3,5-*trans*. Catalytic hydrogenation of (±)-12b gave a γ-hydroxy-α-amino acid (±)-13. Next, in order to transform (±)-13 to racemic allylglycine (±)-14, we examined the olefination of (±)-13 under various conditions. Desilylating reagents such as KF and n-Bu<sub>4</sub>NF were inactive for the reaction. We found that BF<sub>3</sub>-Et<sub>2</sub>O was the best reagent for the olefination of (±)-13. Thus, (±)-13 was treated with BF<sub>3</sub>-Et<sub>2</sub>O in acetonitrile at room temperature for 3 h to give allylglycine (±)-14 in quantitative yield. Though hydrochloric acid also catalyzed the reaction in high yield, a longer reaction time was required (hydrochloric acid-MeOH at room temperature for 6 days) and γ-trimethylsilylmethyl-α-amino-γ-lactone was formed as a by-product.



Scheme 3

According to this procedure, we intended to synthesize the enantiomerically pure allylglycine (+)-**14** from the chiral nitron **4**. The chiral nitron **4** underwent 1,3-dipolar cycloaddition with allyltrimethylsilane under high pressure or in the presence of BF<sub>3</sub>·Et<sub>2</sub>O to give the adduct **15** as a single isomer in 90% yield. The reaction proceeded with the *exo* transition state as the same in the case of the reaction of **10** with allyltrimethylsilane. Therefore, allyltrimethylsilane approached from the less hindered side of **4** as shown in Scheme 4 to give **15** selectively. The structure of **15** was determined to be (3*R*, 7*aS*, 6*S*) by NOE experiment. Thus, 5.4% and 7.1% increase in integration of 7-Ha and 7-Hb were observed by irradiation of 6-H and 7a-H, respectively (Scheme 4). Treatment of **15** with 0.15 M aqueous sodium hydroxide solution at room temperature for 4 h followed by treatment with ion exchange resin (Amberlite IRC-50, acid form) gave the cyclic amino acid (isoxazolidine derivative) (-)-**12b** in almost quantitative yield, concomitant with the quantitative recovery of **3**. Hydrogenolysis of (-)-**12b** with Pd-C gave (2*S*, 4*S*)-2-amino-4-hydroxy-5-(trimethylsilyl)pentanoic acid [(-)-**13**] in 88% yield, whose optical purity was determined to be *ca.* 100% *ee* by HPLC analysis using chiral column (CROWNPAK-CR). As the same in the case of racemic series, (-)-**13** was treated with BF<sub>3</sub>·Et<sub>2</sub>O in CH<sub>3</sub>CN to give the desired enantiomerically pure (*S*)-allylglycine [(-)-**14**].<sup>15</sup> The optical purity of (-)-**14** was also determined to be *ca.* 100% *ee* by comparison of the HPLC analysis of racemic allylglycine [(±)-**14**].




Scheme 4

Employing the same procedure, the EPC synthesis of (*R*)-allylglycine ((+)-14) from the nitrone **5** was also achieved. As in the case of the reaction with **4**, allyltrimethylsilane would approach from the **a**-side of **5** to give the adduct **16** as a sole product. The NOE effects were observed between 6-H and 7-Ha, and between 7-Hb and 7a-H, respectively (Scheme 5). Transformation of **16** to (+)-14 (via (+)-12b and (+)-13) was accomplished by similar procedure given for the synthesis of (-)-14 from **15**.

On the contrary, the chiral nitrone **7** reacted with allyltrimethylsilane under the same conditions to give the *exo* adduct **17**, whose <sup>1</sup>H-NMR spectrum showed **17** to be a mixture of two diastereomers with 60% *de* which were chromatographically inseparable. The adduct **17** was also converted to (*S*)-allylglycine [(-)-14] with 60% *ee*. The *ee* was reflected on the diastereoselectivity in the formation of the adduct **17**.

Reaction of the chiral nitrone **9** with allyltrimethylsilane also took place under high pressure (800 MPa) to give **18** and its diastereomer **19** in 62% and 8% yields, respectively. Both compounds were again formed by the *exo* transition state, and their structures were determined by NOE experiment. The adduct **18** should serve as a precursor of (*R*)-allylglycine [(+)-14].

No *endo* adduct was detected in all 1,3-dipolar cycloadditions of the chiral nitrones **4**, **5**, **7**, and **9** with allyltrimethylsilane. This would be probably due to the steric interaction between the corresponding chiral auxiliaries and the dipolarophile.




Scheme 5

To apply the EPC synthetic method of allylglycine to the asymmetric synthesis of naturally occurring cyclopentenyl amino acid (2*S*,1'*S*)-**28** being a potent growth inhibitor of *Escherichia coli* <sup>16</sup> as well as a biogenic precursor of unusual cyclopentenyl fatty acids,<sup>17</sup> we examined the asymmetric 1,3-dipolar cycloaddition of chiral nitron **4** with 3-trimethylsilylcyclopent-1-ene. Before investigating the asymmetric

reaction, we tried the reaction of achiral nitrone **10** with 3-trimethylsilylcyclopent-1-ene as a preliminary experiment. When the nitrone **10** was allowed to react with 3-trimethylsilylcyclopent-1-ene in  $\text{CH}_2\text{Cl}_2$  under high pressure, three products **20**, **21**, and **22** were obtained in 70%, 13%, and 13% yields, respectively. These compounds were not separated by chromatography, and therefore these yields were determined by 300 MHz  $^1\text{H}$ -NMR data. All products were determined to be the *exo* adducts because the  $^1\text{H}$ -NMR spectra showed a singlet signal due to 8b-H of all adducts **20–22**. On the basis of  $^1\text{H}$ -NMR spectra analysis as shown in Experimental section, it was determined that the minor product **21** corresponded to the stereoisomer of the major product **20** in the 6-position, and compound **22** was a regioisomer of **20** because in the  $^1\text{H}$ -NMR spectra of **20** and **21** 5a-H was observed as a signal of double of doublet (dd) and triplet (t), respectively, whereas that of **22** showed the peak of double of triplet (dt).

In a similar fashion, the asymmetric reaction of chiral nitrone **4** with 3-trimethylsilylcyclopent-1-ene gave three products **23–25** in 55%, 20%, and 24% yield, respectively, which were chromatographically separable from one another. The stereo- and regio-chemistry of compounds **23–25** completely coincided with those of racemic series **20–22**, respectively. The structures of **23** and **25** were eventually confirmed by NOE experiment as shown in Scheme 6 and Table 1.




Scheme 6

**Table 1.** NOE Experiments of Compounds **23** and **25**.

| Irradiated Protons | Increase in Integration (%) |      | Irradiated Protons | Increase in Integration (%) |     |
|--------------------|-----------------------------|------|--------------------|-----------------------------|-----|
| 8a-H               | 5a-H                        | 10.0 | 8a-H               | 8-H                         | 0.7 |
| 8a-H               | TMS                         | 0.0  | 8a-H               | 5a-H                        | 6.7 |
| 5a-H               | 8a-H                        | 8.8  | 8-H                | 8a-H                        | 1.3 |
| 5a-H               | TMS                         | 0.6  | 8-H                | 5a-H                        | 0.0 |
| TMS                | 8a-H                        | 1.4  | 5a-H               | 8a-H                        | 8.1 |
| TMS                | 5a-H                        | 7.5  | 5a-H               | 8-H                         | 0.0 |
|                    |                             |      | TMS                | 8-H                         | 3.9 |
|                    |                             |      | TMS                | 5a-H                        | 0.0 |
|                    |                             |      | TMS                | 8a-H                        | 6.7 |


Since the 1,3-dipolar cycloaddition of nitrones **10** and **4** with 3-trimethylsilylcyclopent-1-ene did not proceed with high regio- and stereo-selectivity, these reactions were not versatile from viewpoint of synthetic chemistry. Therefore, in order to improve the regio- and stereo-selectivity, we examined Lewis acid mediated 1,3-dipolar cycloaddition of nitrones **10** and **4** with 3-trimethylsilylcyclopent-1-ene. When the nitrone **10** was treated with 3-trimethylsilylcyclopent-1-ene in the presence of one equivalent of  $\text{BF}_3\text{-Et}_2\text{O}$  at room temperature, the adduct **20** was obtained as a single isomer in 96% yields. Asymmetric 1,3-dipolar reaction of **4** with 3-trimethylsilylcyclopent-1-ene under the same conditions also proceeded with very high diastereoselectivity to give the adduct **23** as a sole product in 69% yields. These remarkably selective reaction was due to the coordination of  $\text{BF}_3$  with the oxygen atom of nitrones **10** and **4** as shown in Scheme 7. Thus, the coordination increased the reactivity of the nitrones by decrease of LUMO energy of 1,3-dipolar, and caused the steric hindrance in the transition state to improve the diastereoselectivity. Therefore, in the asymmetric 1,3-dipolar cycloaddition, the nitrone coordinated with  $\text{BF}_3$  recognized exclusively only one enantiomer (3*S*-isomer) of 3-trimethylsilylcyclopent-1-ene to form **23** as a single isomer. This means that a novel kinetic resolution of the dipolarophile is involved in the asymmetric 1,3-dipolar cycloaddition.<sup>18</sup> The adduct **20** was then subjected to alkaline hydrolysis with aqueous  $\text{NaHCO}_3$ , hydrogenolysis with  $\text{Pd-C}$ , and olefination with  $\text{BF}_3\text{-Et}_2\text{O}$ , successively, to give racemic cyclopentenylglycine ( $\pm$ )-**28**. Employing the similar procedure, chiral adduct **23** was also converted to the chiral amino acid, (2*S*, 1'*S*)-cyclopentenylglycine (2*S*, 1'*S*)-**28** as an enantiomerically pure compound (EPC), which has the same configuration as the natural product isolated from *Hydnocarpus anthelminthica* and *Caloncoba echinata*.<sup>20</sup> The asymmetric synthesis of cyclopentenylglycine (2*S*, 1'*S*)-**28** has been first carried out by Williams and his coworkers, who have obtained an optically active cyclopentenylglycine as a 1:1 mixture of epimers at the cyclopentene methine.<sup>21</sup> We have achieved the first EPC synthesis of cyclopentenylglycine (2*S*, 1'*S*)-**28**.<sup>10</sup>



Scheme 7

Previously, we reported the reaction of **10** with cyclopentadiene without solvent at atmospheric pressure or in dichloromethane under high pressure to give the *exo* adduct **E** selectively, which was converted to the cyclopentylglycine (±)-**32** in two steps.<sup>6</sup> In order not only to clarify if cyclopentene being less active than 3-trimethylsilylcyclopent-1-ene or cyclopentadiene behaves as a dipolarophile of nitrones **4** or **10** but also to synthesize chiral (-)-**32**, we examined the 1,3-dipolar cycloaddition of **4** or **10** with cyclopentene under various conditions. The nitrone **10** did not react with cyclopentene in an organic solvent at room temperature or on heating. Although  $\text{BF}_3 \cdot \text{Et}_2\text{O}$  also catalyzed the reaction of **10** with cyclopentene in  $\text{CH}_3\text{CN}$  to give the *exo* adduct **29** in 32% yield, the reaction without the catalyst and solvent gave a better yield (73%) of **29**. The quantitative yield of **29** was obtained under high pressure without solvent at room temperature. Therefore, high pressure was also applied for the asymmetric 1,3-dipolar addition of **4** with cyclopentene. The adduct **30** was obtained as a single product in quantitative yield. Transformation of the adducts **29** and **30** to the isoxazolidine derivatives (±)-**31** and (+)-**31** by alkaline hydrolysis was unsuccessful. However, we found that treatment of both compounds with dioxane- $\text{H}_2\text{O}$  at room temperature afforded (±)-**31** and (+)-**31** in good yield,


respectively. Finally, catalytic hydrogenation of ( $\pm$ )-**31** and (+)-**31** gave cyclopentylglycine ( $\pm$ )-**32** and (+)-**32**, respectively.



**Scheme 8**

The nitrones **10** and **4** reacted with norbornadiene at room temperature to form the *exo* adducts **33** and **34** as single isomers. Although the reactions were also accelerated by BF<sub>3</sub>-Et<sub>2</sub>O, the reactions without solvent afforded the best results, whose yields were almost quantitative. Hydrolysis of **33** and **34** was achieved by treatment with SiO<sub>2</sub> in dioxane-H<sub>2</sub>O to form cyclic amino acids ( $\pm$ )-**35** and chiral-**35**, which were then subjected to catalytic reduction using Pd-C to give norbornylglycines ( $\pm$ )-**36** and (-)-**36**, respectively. The optical purity of (-)-**36** was again determined by HPLC to be more than 98 % *ee*.

In conclusion, we have developed a new synthetic method of chiral spiro nitrones *via* nitrosoketene (**2**), which serves as new chiral 1,3-dipolar. We have found that the 1,3-dipolar cycloaddition of nitrones thus obtained with olefins proceeds with the *exo* transition state irrespective to dipolarophiles and the reaction conditions to form diastereoselectively the isoxazolidine derivatives. We have also found that BF<sub>3</sub> is a powerful Lewis acid catalyst for the diastereoselective 1,3-dipolar cycloaddition using the cyclic nitrones, and have achieved the EPC synthesis of nonproteinogenic amino acids. The chiral nitrones synthesized in the present work would be versatile synthons not only for the EPC synthesis of amino acids but also for the chiral synthesis of biologically active substances such as nucleoside analogs containing an amino acid residue. Study on the synthesis of these products is also in progress and the results will be reported in due course.



Scheme 9

### Experimental Section

All melting points were determined on a Yanagimoto micro-hot stage and are uncorrected. IR spectra were measured on a JASCO-102 spectrophotometer and optical rotations were measured with a JASCO DIP-340 digital polarimeter.  $^1\text{H-NMR}$  spectra were recorded on a JEOL JNM-PMX 60 SI, Hitachi R-3000, Varian Gemini-300L or JEOL GX-500 spectrometer with tetramethylsilane as an internal standard. Most  $^1\text{H-NMR}$  spectra were shown as selected data. High-resolution mass spectra were recorded on a JEOL JMS-DX-303 or JMS-AX-500 spectrometer. Enantiomeric excesses (*ees*) were determined by HPLC (high-performance liquid chromatography) analyses using a chiral column (CROWNPAK-CR). HPLC analyses were carried out on a Water Associates instrument (M 6000 pump; U6K injector) using a 220 or 254 nm UV or RI detector. Wakogel (C-200) and Merck Kiesel-gel 60F 254 were employed for silica gel column and thin layer chromatography (TLC), respectively. The ratios of solvent mixtures for chromatography are shown as volume / volume. High pressure reactions were carried out by using a piston-cylinder apparatus equipped with a PK. 15. B pump (Hikari Koatsu Kiki Ltd., Co.).

#### Reaction of (-)-Menthone (3) with 5-Hydroxyimino-2,2-dimethyl-1,3-dioxane-4,6-dione (1)

A solution of 1 (1.73 g, 10 mmol) and 3 (6.16 g, 40 mmol) in toluene (30 ml) was heated under reflux for 2 h. After evaporation of the solvent, the residue was subjected to silica gel (100 g) column chromatography. Elution with hexane-ethyl acetate (10:1) gave 4 (0.59 g, 26%) as colorless needles, mp 102-103 °C (pentane), 5 (0.63 g, 28%) as colorless oil, and the most polar compound (0.31 g, 14%) as colorless oil, successively.

(5*R*, 6*S*, 9*R*)-6-Isopropyl-9-methyl-2-oxo-4-aza-1-oxaspiro[5.4]dec-3-ene 4-Oxide (4):  $[\alpha]_{\text{D}}^{20} +88.8^\circ$  ( $c = 0.50$ ,  $\text{CHCl}_3$ ). IR ( $\text{CHCl}_3$ ): 1780, 1557  $\text{cm}^{-1}$ .  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ , 300 MHz)  $\delta$ : 0.73 (3H,

d,  $J = 6.8$  Hz, CH<sub>3</sub>), 0.94 (3H, d,  $J = 6.8$  Hz, CH<sub>3</sub>), 0.97 (3H, d,  $J = 6.8$  Hz, CH<sub>3</sub>), 7.00 (1H, s, N=CH). *Anal.* Calcd for C<sub>12</sub>H<sub>19</sub>NO<sub>3</sub>: C, 63.97; H, 8.50; N, 6.22. Found: C, 63.97; H, 8.56; N, 6.16.

**[5*S*, 6*S*, 9*R*]-6-Isopropyl-9-methyl-2-oxo-4-aza-1-oxaspiro[5.4]dec-3-ene 4-oxide (5):**  $[\alpha]_{\text{D}}^{20} -35.6^\circ$  ( $c = 0.50$ , CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 1777, 1560 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 0.83 (3H, d,  $J = 7.5$  Hz, CH<sub>3</sub>), 0.92 (3H, d,  $J = 7.5$  Hz, CH<sub>3</sub>), 0.98 (3H, d,  $J = 5.8$  Hz, CH<sub>3</sub>), 7.05 (1H, s, N=CH). High-resolution MS  $m/z$  Calcd for C<sub>12</sub>H<sub>19</sub>NO<sub>3</sub> (M<sup>+</sup>): 225.1365. Found: 225.1378.

The most polar compound:  $[\alpha]_{\text{D}}^{20} -9.6^\circ$  ( $c = 0.50$ , CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 1772, 1561 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 0.87 (3H, d,  $J = 7.0$  Hz, CH<sub>3</sub>), 0.92 (3H, d,  $J = 7.0$  Hz, CH<sub>3</sub>), 1.15 (3H, d,  $J = 7.5$  Hz, CH<sub>3</sub>), 7.07 (1H, s, N=CH). High-resolution MS  $m/z$  Calcd for C<sub>12</sub>H<sub>19</sub>NO<sub>3</sub> (M<sup>+</sup>): 225.1365. Found: 225.1371.

**(5*R*, 6*R*, 8*S*)-7,7-Dimethyl-2-oxo-6,8-methano-4-aza-1-oxaspiro[5.4]dec-3-ene 4-Oxide (7)**

A solution of **1** (173 mg, 1 mmol) and **6** (552 mg, 4 mmol) in toluene (5 ml) was heated under reflux for 2 h. After evaporation of the solvent, the residue was subjected to silica gel (10 g) column chromatography. Elution with hexane-ethyl acetate (10:1) gave **7** (130 mg, 62 %) as colorless prisms, mp 77–78 °C (hexane).  $[\alpha]_{\text{D}}^{22} -136.4^\circ$  ( $c = 1.00$ , CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 1779, 1565 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.09 (3H, s, CH<sub>3</sub>), 1.32 (3H, s, CH<sub>3</sub>), 6.98 (1H, s, N=CH). *Anal.* Calcd for C<sub>11</sub>H<sub>15</sub>NO<sub>3</sub>: C, 63.14; H, 7.23; N, 6.69. Found: C, 62.98; H, 7.23; N, 6.65.

**(5*S*, 7*R*, 10*S*)-6,6-Dimethyl-2-oxo-7,10-methano-4-aza-1-oxaspiro[5.4]dec-3-ene 4-Oxide (9)**

A mixture of **1** (0.865 g, 5 mmol) and **8** (2.760 g, 20 mmol) in toluene (20 ml) was heated under reflux for 2 h. After evaporation of the solvent, the residue was subjected to silica gel (50 g) column chromatography. Elution with hexane-ethyl acetate (10:1) gave **9** (0.533 g, 51 %) as a colorless oil.  $[\alpha]_{\text{D}}^{15} +11.3^\circ$  ( $c = 1.60$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 1.06 (3H, s, CH<sub>3</sub>), 1.15 (3H, s, CH<sub>3</sub>), 1.40 (1H, br dt,  $J = 11.0$ , 1.1 Hz, 11-H), 1.43–1.95 (4H, m), 1.97 (1H, br d,  $J = 2.0$  Hz, 7-H), 2.49 (1H, br d,  $J = 2.8$  Hz, 10-H), 2.66 (1H, br dt,  $J = 11.0$ , 2.0 Hz, 11-H'), 6.90 (1H, s, N=CH). High-resolution MS  $m/z$  Calcd for C<sub>11</sub>H<sub>15</sub>NO<sub>3</sub> (M<sup>+</sup>): 209.1052. Found: 209.1032.

***rel*-(6*S*, 7*aS*)-6-Ethoxy-1-oxo-1,6,7,7*a*-tetrahydroisoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (11*a*)**

According to the procedure previously reported,<sup>6</sup> **11a** was prepared by the reaction of **10** with ethyl vinyl ether. IR (CHCl<sub>3</sub>): 2950, 1778 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$ : 1.21 (3H, t,  $J = 7.0$  Hz, OCH<sub>2</sub>CH<sub>3</sub>), 1.4–1.9 (8H, m, cyclohexyl H), 2.05 (2H, t,  $J = 6.2$ , cyclohexyl H), 2.54 (1H, ddd,  $J = 13.6$ , 9.5, 1.8 Hz, 7-H<sub>b</sub>), 2.88 (1H, ddd,  $J = 13.6$ , 6.2, 1.8 Hz, 7-H<sub>a</sub>), 3.47 (1H, dq,  $J = 9.9$ , 7.0 Hz, OCHH'CH<sub>3</sub>), 3.78 (1H, dq,  $J = 9.9$ , 7.0 Hz, OCHH'CH<sub>3</sub>), 4.23 (1H, dd,  $J = 9.5$ , 1.8 Hz, 7*a*-H), 5.15 (1H, dd,  $J = 6.2$ , 1.8 Hz, 6-H). High-resolution MS  $m/z$  Calcd for C<sub>12</sub>H<sub>19</sub>NO<sub>4</sub> (M<sup>+</sup>): 241.1314. Found: 241.1324. The NOE experiment was carried out by using 500 MHz <sup>1</sup>H-NMR spectrometer. The results were shown in Scheme 3.

***rel*-(6*S*, 7*aS*)-6-[(Trimethylsilyl)methyl]-1-oxo-1,6,7,7*a*-tetrahydroisoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (11*b*)**

According to the procedure previously reported,<sup>6</sup> **11b** was prepared by the reaction of **10** with allyltrimethylsilane. High-resolution MS *m/z* Calcd for C<sub>14</sub>H<sub>25</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 283.1604. Found: 283.1624. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$ : 0.30 (9H, s, TMS), 0.84 (1H, dd, *J* = 14.29, 6.59 Hz, CHH'TMS), 1.01 (1H, dd, *J* = 14.3, 7.7 Hz, CHH'TMS), 1.40-1.82 (10H, m, cyclohexyl H), 2.14 (1H, ddd, *J* = 12.5, 9.9, 8.1 Hz, 7-Hb), 2.70 (1H, dd, *J* = 12.5, 4.8 Hz, 7-Ha), 3.96-4.09 (1H, m, 6-H), 4.25 (1H, d, *J* = 8.1 Hz, 7a-H). The NOE experiment was carried out by using 500 MHz <sup>1</sup>H-NMR spectrometer. The results were shown in Scheme 3.

#### (±)-Allylglycine [(±)-**14**]

To a solution of (±)-**13**<sup>6</sup> (103 mg, 0.5 mmol) in CH<sub>3</sub>CN (14 ml) was added BF<sub>3</sub>·Et<sub>2</sub>O (284 mg, 2 mmol) in argon atmosphere under ice-cooling. After stirring under ice-cooling for 1 h, the solvent was evaporated off *in vacuo*. The residue was dissolved in water (2 ml), and the solution was passed through ion exchange resin (Dowex 50W-X4). The eluate was condensed *in vacuo* to give (±)-**14** (46 mg, 80%) as colorless needles, mp 155-157 °C (MeOH)(*lit.*<sup>22</sup>, 158-159 °C). <sup>1</sup>H-NMR (D<sub>2</sub>O, 300 MHz)  $\delta$ : 2.55-2.77 (2H, m, 3-H), 3.74 (1H, dd, *J* = 7.3, 4.8 Hz, 2-H), 5.23-5.37 (2H, m, 5-H), 5.81 (1H, ddt, *J* = 17.1, 10.0, 7.1 Hz, 4-H).

#### (3*R*,6*S*,7*aS*,1'*R*,4'*S*)-1-Oxo-6-[(trimethylsilyl)methyl]-1,6,7,7*a*-tetrahydroisoxazolo[2,3-*c*]oxazole-3-spiro-3'-menthane (**15**)

1) A solution of the nitrone **4** (225 mg, 1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) and allyltrimethylsilane (1.30 g, 11.4 mmol) were placed in Teflon tube (4 ml) with a Teflon stopper. The tube was placed in a high pressure reactor and pressurized to 800 MPa at 40 °C for 2 d (or at room temperature for 5 d). The pressure was released after the reaction. After evaporation of the solvent and excess allyltrimethylsilane, the residue was subjected to silica gel (50 g) column chromatography. Elution with hexane-ethyl acetate (6:1) gave **15** (308 mg, 91%) as colorless needles, mp 89-91 °C (pentane). [ $\alpha$ ]<sub>D</sub><sup>21</sup> +18.6 ° (*c* = 2.93, CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$ : 0.90 (3H, d, *J* = 6.7 Hz, 8'-CH<sub>3</sub>), 0.91 (3H, d, *J* = 6.7 Hz, 8'-CH<sub>3</sub>), 0.95 (3H, d, *J* = 6.3 Hz, 1'-CH<sub>3</sub>), 2.16 (1H, ddd, *J* = 12.5, 11.5, 8.8 Hz, 7-Hb), 2.67 (1H, dd, *J* = 12.5, 3.8 Hz, 7-Ha), 3.84-3.92 (1H, m, 6-H), 4.14 (1H, d, *J* = 8.8 Hz, 7a-H). High-resolution MS *m/z* Calcd for C<sub>18</sub>H<sub>33</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 339.2230. Found: 339.2231. *Anal.* Calcd for C<sub>18</sub>H<sub>33</sub>NO<sub>3</sub>Si: C, 63.67; H, 9.80; N, 4.13. Found: C, 63.48; H, 9.85; N, 4.07.

2) To a solution of the nitrone **4** (225 mg, 1 mmol) in CH<sub>3</sub>CN (1 ml) was added BF<sub>3</sub>·Et<sub>2</sub>O (142 mg, 1 mmol) under ice-cooling in argon atmosphere. After stirring under ice-cooling for 15 min, allyltrimethylsilane (137 mg, 1.2 mmol) was added to the solution. The mixture was stirred for 2 d at room temperature. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (10 ml), and washed with *aq.* sodium bicarbonate. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>. After evaporation of the solvent and excess of allyltrimethylsilane, the residue was subjected to silica gel (50 g) column chromatography. Elution with hexane-ethyl acetate (6:1) gave (+)-**15** (305 mg, 90%) of colorless needles (pentane).

#### (3*S*,5*S*)-5-[(Trimethylsilyl)methyl]isoxazolidine-3-carboxylic Acid [(-)-**12b**]

1) A suspension of **15** (339 mg, 1 mmol) and sodium hydroxide (80 mg, 2 mmol) in water (2 ml) was stirred for 24 h. (-)-Menthone (**3**) (154 mg, 100 %) was extracted with ether, and the aqueous layer was passed through ion exchange resin (IRC-50S) and the solution was condensed *in vacuo* to give the amino acid (-)-**12b**

(191 mg, 94%).  $[\alpha]_{\text{D}}^{20}$  -28.9 ° ( $c = 12.70$ , MeOH).  $^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ , 300 MHz)  $\delta$ : 0.84 (1H, dd,  $J = 14.0$ , 8.7 Hz,  $\text{CHHTMS}$ ), 1.04 (1H, dd,  $J = 14.0$ , 5.5 Hz,  $\text{CHHTMS}$ ), 2.03 (1H, dt,  $J = 12.0$ , 10.0 Hz, 4-H), 2.35 (1H, ddd,  $J = 12.0$ , 6.0, 4.5 Hz, 4-H), 3.79 (1H, dd,  $J = 10.0$ , 4.5 Hz, 3-H), 3.89- 4.02 (1H, m, 5-H).

2) In a similar manner, (-)-**12b** was also obtained from the adduct **17** using sodium bicarbonate (2 equiv.) instead of sodium hydroxide in 70% yield (from **7**).  $[\alpha]_{\text{D}}^{20}$  -16.5 ° ( $c = 12.70$ , MeOH).

#### (2S,4S)-2-Amino-4-hydroxy-5-(trimethylsilyl)pentanoic Acid [(-)-**13**]

1) A suspension of (-)-**12b** (102 mg, 0.5 mmol) and 5% Pd-C (20 mg) in MeOH (10 ml) was shaken in hydrogen atmosphere under atmospheric pressure at room temperature for 12 h. After removal of the catalyst by Celite filtration, the filtrate was condensed *in vacuo* to give a residue, which was subjected to silica gel (50 g) column chromatography. Elution with EtOAc-acetone-MeOH-H<sub>2</sub>O (8:1:1:1) gave (-)-**13** (90 mg, 88%) of colorless needles (MeOH-EtOAc), mp 174-175 °C. The *ee* of (-)-**13** was determined to be 100% by HPLC analysis using CROWNPAK-CR (solvent: pH 2.0 HClO<sub>4</sub> - H<sub>2</sub>O / MeOH = 85 / 15).  $[\alpha]_{\text{D}}^{28}$  -21.6 ° ( $c = 1.00$ , MeOH),  $^1\text{H-NMR}$  ( $\text{CD}_3\text{OD}$ , 300 MHz)  $\delta$ : 0.07 (9H, s, TMS), 0.88 (1H, dd,  $J = 14.5$ , 7.0 Hz,  $\text{CHHTMS}$ ), 0.97 (1H, dd,  $J = 14.5$ , 7.0 Hz,  $\text{CHHTMS}$ ), 1.91 (1H, ddd,  $J = 15.0$ , 9.3, 4.2 Hz, 3-H), 2.03 (1H, ddd,  $J = 15.0$ , 6.7, 3.0 Hz, 3-H), 3.75 (1H, dd,  $J = 6.7$ , 4.2 Hz, 2-H), 3.97-4.09 (1H, m, 4-H). High-resolution MS  $m/z$  Calcd for C<sub>5</sub>H<sub>9</sub>NO<sub>2</sub> (M<sup>+</sup>-TMSOH): 115.0633. Found: 115.0599.

2) In a similar manner, (-)-**13** was also obtained from (-)-**12b** derived from the adduct **17** in 79% yield.  $[\alpha]_{\text{D}}^{28}$  -13.6 ° ( $c = 1.00$ , MeOH), 60% *ee*, mp 155-170 °C.

#### (S)-Allylglycine [(-)-**14**]

1) According to the procedure given for the preparation of ( $\pm$ )-**14**, (-)-**13** (103 mg, 0.5 mmol) was treated with BF<sub>3</sub>-Et<sub>2</sub>O (284 mg, 2 mmol) to give (-)-**14** (46 mg, 80%) of colorless needles, mp 248-249 °C.  $[\alpha]_{\text{D}}^{26}$  -32.4 ° ( $c = 1.00$ , H<sub>2</sub>O) [*lit.*<sup>20</sup>  $[\alpha]_{\text{D}}^{24}$  -37.1 ° ( $c = 4.00$ , H<sub>2</sub>O)] . The *ee* was determined to be more than 99% by HPLC analysis using CROWNPAK-CR (solvent: pH 1.0 *aq.* HClO<sub>4</sub>). The  $^1\text{H-NMR}$  spectrum of (-)-**14** was identical with that of ( $\pm$ )-**14**.

2) Similarly, (-)-**14** was obtained from (-)-**13** derived from the adduct **17** with two steps in 87% yield.  $[\alpha]_{\text{D}}^{26}$  -21.4 ° ( $c = 1.00$ , H<sub>2</sub>O), 60% *ee*.

#### (3S,6R,7aR,1'R,4'S)-1-Oxo-6-[(trimethylsilyl)methyl]-1,6,7,7a-tetrahydroisoxazolo[2,3-c]oxazole-3-spiro-3'-menthane (**16**)

1) According to the procedure given for the preparation of **15**, the nitrone **5** (225 mg, 1 mmol) was reacted with allyltrimethylsilane (1.30 g, 11.3 mmol) under high pressure at 40 °C for 2 d (or at room temperature for 5 d) to give **16** (312 mg, 92 %) as a colorless oil.  $[\alpha]_{\text{D}}^{22}$  -37.4 ° ( $c = 2.93$ , CHCl<sub>3</sub>).  $^1\text{H-NMR}$  (CDCl<sub>3</sub>, 300MHz)  $\delta$ : 0.73 (3H, d,  $J = 6.8$  Hz, 8'-CH<sub>3</sub>), 0.91 (3H, d,  $J = 6.8$  Hz, 8'-CH<sub>3</sub>), 0.95 (3H, d,  $J = 6.2$  Hz, 1'-CH<sub>3</sub>), 2.13 (1H, ddd,  $J = 12.2$ , 11.1, 8.7 Hz, 7-Hb), 2.63 (1H, dd,  $J = 12.2$ , 4.0 Hz, 7-Ha), 3.73-3.86 (1H, m, 6-H), 4.17 (1H, d,  $J = 8.7$  Hz, 7a-H). High-resolution MS  $m/z$  Calcd for C<sub>18</sub>H<sub>34</sub>NO<sub>3</sub>Si (M<sup>+</sup>+1): 340.2308. Found: 340.2318.

2) According to the procedure given for the preparation of **15**, the nitrone **5** (225 mg, 1 mmol) was reacted with allyltrimethylsilane (137 mg, 1.2 mmol) in the presence of BF<sub>3</sub>-Et<sub>2</sub>O (142 mg, 1 mmol) at room temperature for 2 d to give **16** (305 mg, 90%) as a colorless oil.

**(3*R*,5*R*)-5-[(Trimethylsilyl)methyl]isoxazolidine-3-carboxylic Acid [(+)-12b]**

According to the procedure given for the preparation of (-)-12b, **16** (339 mg, 1 mmol) was treated with aq. sodium hydroxide to give the amino acid (+)-12b (190 mg, 93 %) and (-)-menthone (154 mg, 100%).  $[\alpha]_{\text{D}}^{20} +29.0^\circ$  ( $c=12.50$ , MeOH).

**(2*R*,4*R*)-2-Amino-4-hydroxy-5-(trimethylsilyl)pentanoic Acid [(+)-13]**

According to the procedure given for the preparation of (-)-13, (+)-12b (102 mg, 0.5 mmol) was subjected to hydrogenolysis using 5% Pd-C (20 mg) in MeOH (10 ml) to give (+)-13 (90 mg, 88%) as colorless needles (MeOH-EtOAc), mp 174-175 °C.  $[\alpha]_{\text{D}}^{28} +21.6^\circ$  ( $c=1.00$ , MeOH). The <sup>1</sup>H-NMR spectrum of (+)-13 was identical with that of (-)-13.

**(*R*)-Allylglycine [(+)-14]**

According to the procedure given for the preparation of (-)-14, (+)-13 (103 mg, 0.5 mmol) was treated with BF<sub>3</sub>·Et<sub>2</sub>O (284 mg, 2 mmol) to give (+)-14 (46 mg, 80%) as colorless needles.  $[\alpha]_{\text{D}}^{24} +33.5^\circ$  ( $c=1.00$ , H<sub>2</sub>O). The *ee* was determined to be more than 99% by HPLC analysis using CROWNPAK-CR (solvent: pH 1.0 aq. HClO<sub>4</sub>).

**(3*R*,6*S*,7*aS*,1'*R*,5'*S*)-1-Oxo-6-[(trimethylsilyl)methyl]-1,6,7,7*a*-tetrahydroisoxazolo[2,3-*c*]oxazole-3-spiro-2'-(6',6'-dimethylbicyclo[3.1.1]heptane) (17)**

According to the procedure given for the preparation of **16**, **7** (209 mg, 1 mmol) was reacted with allyltrimethylsilane (1.30 g, 11.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) at 800 MPa for 17 h to give **17** (323 mg, quant.), which was used for the preparation of (-)-12b without further purification. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300MHz)  $\delta$ : 4.02 (4/5 H, d,  $J=8.1$  Hz, 7a-H), 4.12 (1/5 H, d,  $J=8.2$  Hz, 7a-H).

**(3*S*,6*R*,7*aR*,1'*R*,4'*S*)-1-Oxo-6-[(trimethylsilyl)methyl]-1,6,7,7*a*-tetrahydroisoxazolo[2,3-*c*]oxazole-3-spiro-3'-(2',2'-dimethylbicyclo[2.2.1]heptane) (18)**

According to the procedure given for the preparation of **16**, the nitron **9** (209 mg, 1 mmol) was reacted with allyltrimethylsilane (1.30 g, 11.3 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) under 800 MPa at 40 °C for 69 h to give **18** (200 mg, 62%) and **19** (26 mg, 8%), respectively. These products were purified by silica gel (50 g) column chromatography using hexane-ethyl acetate (6:1).

More polar (**18**):  $[\alpha]_{\text{D}}^{18} +10.2^\circ$  ( $c=1.9$ , CHCl<sub>3</sub>). High-resolution MS  $m/z$  Calcd for C<sub>17</sub>H<sub>29</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 323.1917. Found: 323.1955. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 0.03 (9H, s, TMS), 0.80 (1H, dd,  $J=14.3$ , 6.8 Hz, CHH'TMS), 0.90 (3H, s, 2'-CH<sub>3</sub>), 1.09 (1H, dd,  $J=14.3$ , 7.4 Hz, CHH'TMS), 1.11 (3H, s, 2'-CH<sub>3</sub>), 1.21-2.08 (7H, m), 2.14 (1H, dt,  $J=12.2$ , 8.3 Hz, 7-Hb), 2.69 (1H, dd,  $J=12.2$ , 5.4 Hz, 7-Ha), 2.97 (1H, br d,  $J=3.3$  Hz, 4'-H), 3.97 (1H, br d,  $J=7.2$  Hz, 7a-H), 4.03-4.12 (1H, m, 6-H).

Less polar (**19**): High-resolution MS  $m/z$  Calcd for C<sub>17</sub>H<sub>29</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 323.1917. Found: 323.1936. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 0.01 (9H, s, TMS), 0.87 (1H, dd,  $J=14.2$ , 6.2 Hz, CHH'TMS), 0.94 (3H, s, 2'-CH<sub>3</sub>), 1.00 (1H, dd,  $J=14.2$ , 7.3 Hz, CHH'TMS), 1.06 (3H, s, 2'-CH<sub>3</sub>), 1.21-2.08 (7H, m), 2.16 (1H, dt,  $J=12.3$ , 8.2 Hz, 7-Hb), 2.59 (1H, br d,  $J=3.0$  Hz, 4'-H), 2.72 (1H, dd,  $J=12.3$ , 5.3 Hz, 7-Ha), 3.92-4.05 (1H, m, 7a-H), 4.11 (1H, ddd,  $J=14.2$ , 7.3, 6.9 Hz, 6-H).

### Reaction of the Nitrone 10 with 3-Trimethylsilylcyclopent-1-ene

#### 1) under high pressure

Following the procedure given for the preparation of **11a**, high pressure mediated reaction of **10** (169 mg, 1 mmol) with 3-trimethylsilylcyclopent-1-ene (720 mg, 5 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) for 24 h at room temperature gave **20**, **21**, and **22** which were chromatographically inseparable. The ratio of these compounds were determined to be **20**: **21**: **22** = 70: 13: 13 by <sup>1</sup>H-NMR spectroscopy.

**rel-(5a*S*,6*S*,8a*R*,8b*S*)-1-Oxo-6-[(trimethyl)silyl]-1,5a,8a,8b-tetrahydrocyclopent[*f*]-isoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (20)**: <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 3.22 (1H, dt, *J* = 15.0, 7.5 Hz, 8a-H), 3.85 (1H, s, 8b-H), 4.43 (1H, dd, *J* = 7.5, 5.3 Hz, 5a-H).

**rel-(5a*S*,6*R*,8a*R*,8b*S*)-1-Oxo-6-[(trimethyl)silyl]-1,5a,8a,8b-tetrahydrocyclopent[*f*]-isoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (21)**: <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 0.04 (9H, s, TMS), 3.38 (1H, br t, *J* = 6.7 Hz, 8a-H), 3.81 (1H, s, 8b-H), 4.71 (1H, t, *J* = 6.1 Hz, 5a-H).

**rel-(5a*S*,8*R*,8a*R*,8b*S*)-1-Oxo-8-[(trimethyl)silyl]-1,5a,8a,8b-tetrahydrocyclopent[*f*]-isoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (22)**: <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 0.03 (9H, s, TMS), 3.05 (1H, t, *J* = 8.3 Hz, 8a-H), 3.75 (1H, s, 8b-H), 4.56 (1H, dt, *J* = 6.2, 6.2 Hz, 5a-H).

#### 2) in the presence of BF<sub>3</sub>-Et<sub>2</sub>O

According to the procedure given for the preparation of **15**, **10** (169 mg, 1 mmol) was allowed to react with 3-trimethylsilylcyclopent-1-ene (168 mg, 1.2 mmol) in the presence of BF<sub>3</sub>-Et<sub>2</sub>O (142 mg, 1 mmol) for 14 h at room temperature to give **20** (295 mg, 96%) as a pale yellow oil. IR (CHCl<sub>3</sub>): 1784 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 3.22 (1H, dt, *J* = 15.0, 7.5 Hz, 8a-H), 3.85 (1H, s, 8b-H), 4.43 (1H, dd, *J* = 7.5, 5.3 Hz, 5a-H). High-resolution MS *m/z* Calcd for C<sub>16</sub>H<sub>27</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 309.1760. Found: 309.1755.

### Reaction of the Nitrone 4 with 3-Trimethylsilylcyclopent-1-ene

#### 1) under high pressure

Following the procedure given for the preparation of **11a**, high pressure mediated reaction of **4** (112.5 mg, 0.5 mmol) with 3-trimethylsilylcyclopent-1-ene (140 mg, 1 mmol) under 800 MPa at 40 °C for 48 h gave a mixture of **23**, **24**, and **25** in almost quantitative total yield. The ratio of these compounds were determined to be **23**: **24**: **25** = 55: 20: 24 by 300 MHz <sup>1</sup>H-NMR spectroscopy.

**(3*R*,5a*S*,6*S*,8a*R*,8b*S*,1'*R*,4'*S*)-1-Oxo-6-[(trimethyl)silyl]-1,5a,8a,8b-tetrahydrocyclopent[*f*]isoxazolo[2,3-*c*]oxazole-3-spiro-3'-menthane (23)**: mp 118-120 °C (pentane). [α]<sub>D</sub><sup>23</sup> +88.0 ° (*c* = 1.05, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 1782 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 0.86 (3H, d, *J* = 6.5 Hz, 8'-CH<sub>3</sub>), 0.89 (3H, d, *J* = 6.5 Hz, 8'-CH<sub>3</sub>), 0.90 (3H, d, *J* = 6.5 Hz, 1'-CH<sub>3</sub>), 3.16 (1H, dt, *J* = 15.0, 7.5 Hz, 8a-H), 3.88 (1H, s, 8b-H), 4.31 (1H, dd, *J* = 6.5, 4.5 Hz, 5a-H). High-resolution MS *m/z* Calcd for C<sub>20</sub>H<sub>35</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 365.2384. Found: 365.2361. *Anal.* Calcd for C<sub>20</sub>H<sub>35</sub>NO<sub>3</sub>Si: C, 65.71; H, 9.65; N, 3.83. Found: C, 65.90; H, 9.33; N, 3.72.

**(3*R*,5a*S*,6*R*,8a*R*,8b*S*,1'*R*,4'*S*)-1-Oxo-6-[(trimethyl)silyl]-1,5a,8a,8b-tetrahydrocyclopent[*f*]isoxazolo[2,3-*c*]oxazole-3-spiro-3'-menthane (24)**: <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 0.05 (9H, s, TMS), 3.31 (1H, dt, *J* = 7.5, 5.2 Hz, 8a-H), 3.82 (1H, s, 8b-H), 4.61 (1H, t, *J* = 5.5 Hz, 5a-H).

**(3*R*,5a*S*,8*R*,8a*R*,8b*S*,1'*R*,4'*S*)-1-Oxo-8-[(trimethyl)silyl]-1,5a,8a,8b-tetrahydrocyclopent[*f*]isoxazolo[2,3-*c*]oxazole-3-spiro-3'-menthane (25)**: <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 Mz) δ: 0.04 (9H,

s, TMS), 0.80-2.41 (14H, m), 0.86 (3H, d,  $J = 6.9$  Hz, 8'-CH<sub>3</sub>), 0.89 (3H, d,  $J = 6.9$  Hz, 8'-CH<sub>3</sub>), 0.91 (3H, d,  $J = 6.3$  Hz, 1'-CH<sub>3</sub>), 3.00 (1H, dd,  $J = 9.6, 5.8$  Hz, 8a-H), 3.83 (1H, s, 8b-H), 4.43 (1H, dt,  $J = 5.0, 3.3$  Hz, 5a-H).

2) in the presence of BF<sub>3</sub>-Et<sub>2</sub>O

According to the procedure given for the preparation of **15, 4** (225 mg, 1 mmol) was allowed to react with 3-trimethylsilylcyclopent-1-ene (336 mg, 2.4 mmol) in CH<sub>3</sub>CN (1 ml) in the presence of BF<sub>3</sub>-Et<sub>2</sub>O (142 mg, 1 mmol) at room temperature for 91 h to give **23** (252 mg, 69%) as colorless needles (pentane). mp 118-120 °C. Hexane- ethyl acetate (5:1) was used for silica gel (50 g) column chromatography.

**rel-(3*S*,3*aR*,6*aS*,6*S*)-6-Trimethylsilyl-2,3,3*a*,6*a*-tetrahydrocyclopent[*d*]isoxazole-3-carboxylic Acid [(±)-26]**

A suspension of **20** (309 mg, 1 mmol) and NaHCO<sub>3</sub> (168 mg, 2 mmol) in H<sub>2</sub>O (2 ml) was stirred at room temperature for 24 h. The mixture was extracted with ether to remove cyclohexanone. The aqueous layer was passed through ion exchange resin (IRC-50S). The resulting solution was condensed *in vacuo* to give (±)-**26** (192 mg, 84 %). <sup>1</sup>H-NMR (CD<sub>3</sub>OD, 300 Mz) δ: 1.16-2.06 (5H, m), 2.84-2.96 (1H, m, 3a-H), 3.44 (1H, d,  $J = 5.3$  Hz, 3-H), 4.40 (1H, dd,  $J = 7.0, 2.2$  Hz, 6a-H).

**rel-(2*S*,1'*R*,2'*S*,3'*S*)-2-Amino-2-[2'-hydroxy-3'-(trimethylsilyl)cyclopentyl]acetic Acid [(±)-27]**

A suspension of (±)-**26** (115 mg, 0.5 mmol) and 5% Pd-C (20 mg) in methanol (10 ml) was shaken in H<sub>2</sub> atmosphere at room temperature for 32 h. After removal of the catalyst by Celite filtration, the solvent was evaporated off to give a residue, which was subjected to silica gel (50 g) column chromatography. Elution with EtOAc-acetone-MeOH-H<sub>2</sub>O (7: 1: 1: 1) gave (±)-**27** (96 mg, 83%) as colorless needles, mp 175-178 °C (MeOH-EtOAc). <sup>1</sup>H-NMR (CD<sub>3</sub>OD, 300 Mz) δ: 1.10(1H, dt,  $J = 9.0, 3.5$  Hz, CHTMS), 1.23-2.10 (5H, m), 2.11 (1H, dq,  $J = 12.5, 6.0$  Hz, 1'-H), 3.71 (1H, d,  $J = 6.0$  Hz, 2-H), 4.18 (1H, dd,  $J = 5.5, 3.5$  Hz, 2'-H). High-resolution MS  $m/z$  Calcd for C<sub>10</sub>H<sub>21</sub>NO<sub>3</sub>Si (M<sup>+</sup>): 231.1291. Found: 231.1287.

**rel-(2*S*,1'*S*)-2-Amino-2-(2'-cyclopentenyl)acetic Acid [(±)-28: cyclopentenylglycine]**

To a solution of (±)-**27** (116 mg, 0.5 mmol) in CH<sub>3</sub>CN (14 ml) added BF<sub>3</sub>-Et<sub>2</sub>O (284 mg, 2 mmol) under Ar atmosphere with ice-cooling. The mixture was stirred with ice-cooling for 1 h. After removal of the solvent *in vacuo*, the residue was dissolved in water (5 ml), and the solution was passed through ion exchange resin (Dowex 50W-X4). The solution was condensed *in vacuo* to give (±)-**28** (59 mg, 84%) of mp 260 °C (dec.) as colorless needles. <sup>1</sup>H-NMR (CD<sub>3</sub>OD, 300 MHz) δ: 1.46-2.51 (5H, m), 3.47 (1H, d,  $J = 4.8$  Hz, 2-H), 5.58-5.65 (1H, m, olefinic H), 5.90-5.96 (1H, m, olefinic H'). High-resolution MS  $m/z$  Calcd for C<sub>7</sub>H<sub>12</sub>NO<sub>2</sub> (M<sup>+</sup>+1): 142.0868; C<sub>7</sub>H<sub>11</sub>NO<sub>2</sub> (M<sup>+</sup>): 141.0790. Found: 142.0901; 141.0779.

**(3*S*,3*aR*,6*aS*,6*S*)-6-Trimethylsilyl-2,3,3*a*,6*a*-tetrahydrocyclopent[*d*]isoxazole-3-carboxylic Acid [(+)-26]**

A solution of **23** (437 mg, 1.2 mmol) and NaHCO<sub>3</sub> (202 mg, 2.4 mmol) in THF (15 ml)-H<sub>2</sub>O (15 ml) was stirred at room temperature for 32 h. After evaporation of THF, the residue was extracted with

ether to recover menthone (152 mg, 0.99 mmol, 83%). The aqueous layer was passed through ion exchange resin (IRC-50S). The resulting solution was condensed *in vacuo* to give (+)-**26** (209 mg, 0.91 mmol, 76%).  $[\alpha]_D^{21} +39.6^\circ$  ( $c = 0.50$ , MeOH). The  $^1\text{H-NMR}$  spectrum of (+)-**26** was identical with that of (±)-**26**.

**(2*S*,1'*R*,2'*S*,3'*S*)-2-Amino-2-[2'-hydroxy-3'-(trimethylsilyl)cyclopentyl]acetic Acid [(+)-**27**]**

According to the procedure given for the preparation of (±)-**27**, (+)-**26** (115 mg, 0.5 mmol) was subjected to catalytic reduction using 5% Pd-C to give (+)-**27** (87 mg, 75%). mp 170-171 °C (dec.).  $[\alpha]_D^{24} +13.5^\circ$  ( $c = 0.95$ , MeOH). The *ee* was determined to be more than 99% by HPLC analysis using CROWNPAK-CR (+) (solvent: pH 1.0 HClO<sub>4</sub>-H<sub>2</sub>O / MeOH = 99:1). The  $^1\text{H-NMR}$  spectrum of **27** was identical with that of (±)-**27**.

**(2*S*,1'*S*)-2-Amino-2-(2'-cyclopentenyl)acetic Acid [(2*S*,1'*S*)-**28**: (2*S*,1'*S*)-cyclopentenyl-glycine]**

According to the procedure given for the preparation of (±)-**28**, (+)-**27** (46 mg, 0.2 mmol) was treated with BF<sub>3</sub>-Et<sub>2</sub>O (113 mg, 0.8 mmol) in CH<sub>3</sub>CN (5 ml) for 1.5 h to give (2*S*,1'*S*)-**28** (23 mg, 80%). mp 243-246 °C (dec.).  $[\alpha]_D^{21} -121.3^\circ$  ( $c = 0.32$ , H<sub>2</sub>O). The *ee* was determined to be more than 98% by HPLC analysis using CROWNPAK-CR (+) (solvent: pH 1.0 HClO<sub>4</sub>-H<sub>2</sub>O). The  $^1\text{H-NMR}$  spectrum of (2*S*,1'*S*)-**28** was identical with that of (±)-**28**.

***rel*-(5*aS*,8*aR*,8*bS*)-1-Oxo-1,5*a*,8*a*,8*b*-tetrahydrocyclopent[*f*]isoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (**29**)**

According to the procedure given for the preparation of **15**, **10** (845 mg, 5 mmol) was reacted with cyclopentene (9 ml) without solvent at 800 MPa at 30 °C for 48 h to give **29** (913 mg, quant.), which was used for the preparation of (±)-**31** without further purification.  $^1\text{H-NMR}$  (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 1.37-2.06 (16H, m), 3.31-3.39 (1H, m, 8*a*-H), 3.84 (1H, s, 8*b*-H), 4.64 (1H, t,  $J = 6.2$  Hz, 5*a*-H). High-resolution MS  $m/z$  Calcd for C<sub>13</sub>H<sub>19</sub>NO<sub>3</sub> (M<sup>+</sup>): 237.1365. Found: 237.1356.

***rel*-(3*S*,3*aR*,6*aR*)-2,3,3*a*,6*a*-Tetrahydrocyclopent[*d*]isoxazole-3-carboxylic Acid [(±)-**31**]**

A solution of **29** (913 mg, crude) in dioxane (25 ml) and H<sub>2</sub>O (5 ml) was stirred at room temperature for 48 h. To the reaction mixture was added Et<sub>2</sub>O (40 ml) and H<sub>2</sub>O (40 ml). The resulting mixture was shaken in a separating funnel, and the aqueous layer was condensed *in vacuo* to give (±)-**31** (468 mg, 60% from **10**) as a pale yellow oil.  $^1\text{H-NMR}$  (CD<sub>3</sub>OD, 300 MHz)  $\delta$ : 1.54-1.93 (6H, m), 3.04-3.16 (1H, m), 3.56 (1H, d,  $J = 6.6$  Hz, 3-H), 4.65 (1H, dt,  $J = 5.7, 1.6$  Hz, 6*a*-H). High-resolution MS  $m/z$  Calcd for C<sub>7</sub>H<sub>11</sub>NO<sub>3</sub> (M<sup>+</sup>): 157.0739. Found: 157.0737.

***rel*-(2*S*,1'*R*,2'*R*)-2-Amino-2-(2'-hydroxycyclopentyl)acetic Acid [(±)-**32**]**

A suspension of (±)-**31** (314 mg) and 5% Pd-C (60 mg) in MeOH (3 ml) was stirred in hydrogen atmosphere at room temperature for 24 h. The catalyst was filtered off by using Celite, and the filtrate was subjected to silica gel (10 g) column chromatography. Elution with AcOEt-MeOH-acetone-H<sub>2</sub>O (5:1:1:1) gave (±)-**32** (283 mg, 53% from **29**) of mp 227-229 °C as colorless needles (MeOH), which was identical in every

respect with the authentic sample.<sup>6</sup> <sup>1</sup>H-NMR (CD<sub>3</sub>OD, 300 MHz)  $\delta$ : 1.55-1.95 (6H, m), 2.22-2.36 (1H, m, 1'-H), 3.76 (1H, d,  $J$  = 6.0 Hz, 2-H), 4.33 (1H, dt,  $J$  = 7.0, 2.0 Hz, 2'-H).

**(3R,5aR,8aR,8bS,1'R,4'S)-1-Oxo-1,5a,8a,8b-tetrahydrocyclopent[*f*]isoxazolo[2,3-*c*]-oxazole-3-spiro-3'-menthane (30)**

According to the procedure given for the preparation of **15**, a solution of **4** (675 mg, 3 mmol) in cyclopentene (9 ml) was pressurized at 800 MPa at 30 °C for 72 h. After removal of excess cyclopentene *in vacuo*, a crystalline substance (880 mg, quant.) was obtained, which was purified by recrystallization from Et<sub>2</sub>O-hexane to give **30** (609 mg, 69%) of mp 114-115 °C as colorless needles.  $[\alpha]_D^{24}$  +64.3° ( $c$  = 1.10, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 1765 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 0.87 (3H, d,  $J$  = 6.6 Hz, Me), 0.92 (3H, d,  $J$  = 6.6 Hz, Me), 0.93 (3H, d,  $J$  = 6.6 Hz, Me), 1.30 (1H, t,  $J$  = 12.6 Hz), 1.50-1.95 (13 H, m), 2.390 (1H, dt,  $J$  = 12.6, 2.6 Hz), 3.25-3.35 (1H, m, 8a-H), 3.82 (1H, s, 8b-H), 4.55 (1H, t,  $J$  = 5.4 Hz, 5-H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 75 MHz)  $\delta$ : 18.07, 21.91, 22.95, 23.67, 24.37, 24.87, 29.75, 32.21, 32.88, 34.21, 41.89, 51.17, 51.47, 72.00, 82.47, 108.43, 175.97. *Anal.* Calcd for C<sub>17</sub>H<sub>27</sub>NO<sub>3</sub>: C, 68.29; H, 9.67; N, 4.98. Found: C, 68.20; H, 9.05; N, 4.58.

**(3S,3aR,6aR)-2,3,3a,6a-Tetrahydrocyclopent[*d*]isoxazole-3-carboxylic Acid [(+)-31]**

A solution of **30** (586 mg) in dioxane (10 ml) and H<sub>2</sub>O (2 ml) was stirred at room temperature for 48 h. To the reaction mixture was added Et<sub>2</sub>O (30 ml) and H<sub>2</sub>O (30 ml). The resulting mixture was shaken in a separating funnel, and the aqueous layer was condensed *in vacuo* to give (+)-**31** (263 mg, 84%) of mp 105-108 °C (dec.) as colorless needles (MeOH-AcOEt).  $[\alpha]_D^{22}$  +60.2° ( $c$  = 2.10, MeOH). The <sup>1</sup>H-NMR spectrum was identical with that of (±)-**31**.

**(2S,1'R,2'R)-Amino-2-(2'-hydroxycyclopentyl)acetic Acid [(-)-32]**

A suspension of (+)-**31** (152 mg, 0.97 mmol) and 5% Pd-C (30 mg) was stirred in hydrogen atmosphere at room temperature for 24 h. After removal of the catalyst by using Celite filtration, the filtrate was subjected to silica gel (10 g) column chromatography. Elution with AcOEt-MeOH-acetone-H<sub>2</sub>O (5:1:1:1) gave (-)-**32** (145 mg, 95%) as colorless needles, mp 213-216 °C (dec.) (MeOH-AcOEt).  $[\alpha]_D^{24}$  -53.0° ( $c$  = 0.40, MeOH). The optical purity was determined to be more than 99% by HPLC using CROWNPAK-CR (+) (solvent: pH 2.0, HClO<sub>4</sub>-H<sub>2</sub>O). The <sup>1</sup>H-NMR spectrum was identical with that of the racemic (±)-**32**.

**rel-(5aR,6R,9S,9aR,9bS)-7,8-Dehydro-6,9-methano-1-oxo-1,5a,9a,9b-tetrahydrocyclohex[*f*]isoxazolo[2,3-*c*]oxazole-3-spiro-1'-cyclohexane (33)**

A solution of **10** (169 mg, 1mmol) and norbornadiene (4 mmol) was kept at room temperature for 9 h. After evaporation of excess norbornadiene *in vacuo*, **33** (260 mg) was obtained in quantitative yield, which was used without further purification for the preparation of (±)-**35**. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz)  $\delta$ : 1.39-2.37 (12H, m), 2.89 (1H, s, 6- or 9-H), 2.93 (1H, s, 6- or 9-H), 3.06 (1H, d,  $J$  = 6.5 Hz, 9a-H), 3.89 (1H, s, 9b-H), 4.28 (1H, d,  $J$  = 7 Hz, 5a-H), 6.03 (1H, dd,  $J$  = 5.5, 3.0 Hz, 7- or 8-H), 6.25 (1H, dd,  $J$  = 5.5, 4.0 Hz, 7- or 8-H). High-resolution MS  $m/z$  Calcd for C<sub>15</sub>H<sub>19</sub>NO<sub>3</sub> (M<sup>+</sup>): 261.1365. Found: 261.1405.

***rel*-(3*S*,3*aR*,4*S*,7*R*,7*aR*)-5,6-Dehydro-4,7-methano-2,3,3*a*,7*a*-tetrahydrocyclohex[*d*]-isoxazole-3-carboxylic Acid [(±)-35]**

A suspension of **33** (260 mg) and silica gel (500 mg) in dioxane-H<sub>2</sub>O (3:1, 5 ml) was stirred for 30 h at room temperature. Silica gel was filtered off, and the silica gel was washed with MeOH (10 ml). The combined solution of the filtrate and washings was condensed *in vacuo* to give a residue, to which were added ether (10 ml) and H<sub>2</sub>O (10 ml). The mixture was shaken in a separating funnel. The aqueous layer was condensed *in vacuo* to give (±)-**35** (160 mg, 89 %). Due to its instability, (±)-**35** was used for the preparation of (±)-**36** without further purification. <sup>1</sup>H-NMR (CD<sub>3</sub>OD, 300 MHz) δ: 1.74 (1H, d, *J* = 9.3 Hz, 8-H), 2.00 (1H, d, *J* = 9.3 Hz, 8-H), 2.73 (1H, t, *J* = 6.9 Hz, 3*a*-H), 2.84 (1H, br s, 4- or 7-H), 2.90 (1H, br s, 4- or 7-H), 3.56 (1H, d, *J* = 7.2 Hz, 3-H), 4.42 (1H, d, *J* = 6.6 Hz, 7*a*-H), 6.11 (1H, dd, *J* = 3.2, 5.6 Hz, olefinic H), 6.37 (1H, dd, *J* = 3.2, 5.9 Hz, olefinic H). High-resolution MS *m/z* Calcd for C<sub>9</sub>H<sub>11</sub>NO<sub>2</sub> (M<sup>+</sup>-16): 165.0790. Found: 165.0812.

***rel*-(2*S*,1'*R*,2'*R*,3'*R*,4'*S*)-2-Amino-2-(3'-hydroxy-2'-norbornyl)acetic Acid [(±)-36: (±)-norbornylglycine]**

To a solution of (±)-**35** (160 mg) in MeOH (10 ml) was added 5% Pd-C (30 mg). The mixture was stirred in hydrogen atmosphere for 36 h at room temperature. The catalyst was filtered off by using Celite, and the filtrate was condensed *in vacuo*. The residue was subjected to silica gel (10 g) column chromatography using AcOEt-MeOH-acetone-H<sub>2</sub>O (8:1:1:1) as eluent to give (±)-**36** (74 mg). <sup>1</sup>H-NMR (CD<sub>3</sub>OD, 300 MHz) δ: 1.00–2.05 (7H, m), 2.20 (1H, br s, 1'- or 4'-H), 2.52 (1H, br s, 1'- or 4'-H), 3.58 (1H, d, *J* = 9.6 Hz, 2-H), 3.90 (1H, d, *J* = 6.9 Hz, 3'-H). High-resolution MS *m/z* Calcd for C<sub>9</sub>H<sub>13</sub>NO<sub>2</sub> (M<sup>+</sup>-18): 167.0946. Found: 167.0969.

**(3*R*,5*aR*,6*R*,9*S*,9*aR*,9*bS*,1'*R*,4'*S*)-7,8-Dehydro-6,9-methano-1-oxo-1,5*a*,9*a*,9*b*-tetrahydrocyclohex[*f*]isoxazolo[2,3-*c*]oxazole-3-spiro-3'-menthane (**34**)**

A solution of **4** (225 mg, 1 mmol) in norbornadiene (2 ml) was stirred for 21 h at room temperature. The reaction mixture was condensed *in vacuo* to give a pale yellow crystalline substance **34** (317 mg, 99%). mp 115–117 °C (dec.) (ether-hexane). [α]<sub>D</sub><sup>25</sup> +68.9 ° (*c* = 1.00, CHCl<sub>3</sub>). IR (CHCl<sub>3</sub>): 1770 cm<sup>-1</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>, 300 MHz) δ: 0.85 (3H, d, *J* = 6.9 Hz, 1'-Me), 0.92 (3H, d, *J* = 6.6 Hz, 8'-Me), 0.93 (3H, d, *J* = 6.6 Hz, 8'-Me), 1.27 (1H, t, *J* = 12.6 Hz, 2'-H<sub>ax</sub>), 1.50–1.95 (8H, m), 2.18 (1H, d, *J* = 9.2 Hz, 10-H), 2.49 (1H, dt, *J* = 12.8, 2.6 Hz, 4'-H), 2.87 (1H, br s, 9-H), 2.91 (1H, br s, 6-H), 3.08 (1H, d, *J* = 6.2 Hz, 9*a*-H), 3.79 (1H, s, 9*b*-H), 4.26 (1H, d, *J* = 6.2 Hz, 5*a*-H), 6.03 (1H, dd, *J* = 5.8, 3.0 Hz, olefinic H), 6.24 (1H, dd, *J* = 5.8, 3.0 Hz, olefinic H). High-resolution MS *m/z* Calcd for C<sub>19</sub>H<sub>27</sub>NO<sub>3</sub> (M<sup>+</sup>): 317.1991. Found: 317.2009. *Anal.* Calcd for C<sub>19</sub>H<sub>27</sub>NO<sub>3</sub>: C, 71.89; H, 8.57; N, 4.41. Found: C, 72.39; H, 8.70; N, 4.30.

**(2*S*,1'*R*,2'*R*,3'*R*,4'*S*)-2-Amino-2-(3'-hydroxy-2'-norbornyl) acetic Acid [(−)-36: (−)-norbornylglycine]**


A suspension of **34** (317 mg) and silica gel (500 mg) in dioxane-H<sub>2</sub>O (3:1, 5 ml) was stirred for 30 h at room temperature. Silica gel was filtered off, and the silica gel was washed with MeOH (10 ml). To the combined solution of the filtrate and washings was added 5% Pd-C (30 mg). The mixture was stirred in hydrogen atmosphere for 36 h at room temperature. The catalyst was filter off by using Celite, and the filtrate

was condensed *in vacuo*. The residue was subjected to silica gel (10 g) column chromatography using AcOEt-MeOH-acetone-H<sub>2</sub>O (8:1:1:1) as eluent to give (-)-**36** (74 mg, 40% from **34**).  $[\alpha]_D^{26} -22.8^\circ$  ( $c = 0.71$ , MeOH). The <sup>1</sup>H-NMR spectrum was identical with that of (+)-**36**. The *ee* was determined to be more than 98% by HPLC analysis using CROWNPAK-CR (+) (solvent: pH 1.0, HClO<sub>4</sub>-H<sub>2</sub>O).

**Acknowledgment.** This work was supported in part by a Grant-in-Aid for Scientific Research (No. 0867405 to N. K.) from the Ministry of Education, Science, Sports, and Culture, Japan.

### References and Notes

1. Gong, L.; McAllister, M. A.; Tidwell, T. T. *J. Am. Chem. Soc.* **1991**, *113*, 6021.
2. McAllister, M. A.; Tidwell, T. T. *J. Org. Chem.* **1994**, *59*, 4506.
3. Tidwell, T. T. *Ketenes*; John Wiley & Sons: New York, 1995.
4. Very recently, we have detected nitrosoketene (**2**) generated by pyrolysis of **1** using FT-IR spectroscopy. Matsui, H.; Zuckerman, E. J.; Katagiri, N.; Kaneko, C.; Ham, S.; Birney, D. M. *J. Phys. Chem.* in press.
5. Katagiri, N.; Kurimoto, A.; Yamada, A.; Sato, H.; Katsuhara, T.; Takagi, K.; Kaneko, C. *J. Chem. Soc., Chem. Commun.* **1994**, 281.
6. Katagiri, N.; Sato, H.; Kurimoto, A.; Okada, M.; Yamada, A.; Kaneko, C. *J. Org. Chem.* **1994**, *59*, 8101.
7. Ham, S.; Birney, D. M. *Tetrahedron Lett.* **1994**, *35*, 8113.
8. For a recent review dealing with the stereoselective synthesis of  $\alpha$ -amino acids, see: Duthaler, R. O. *Tetrahedron*, **1994**, *50*, 1539.
9. Katagiri, N.; Okada, M.; Kaneko, C. *Tetrahedron Lett.* **1996**, *37*, 1801.
10. Katagiri, N.; Okada, M.; Morishita, Y.; Kaneko, C. *J. Chem. Soc., Chem. Commun.* **1996**, 2137.
11. In this reaction, the other isomer (more polar than **5**) was also obtained in 14% yield, which would be formed by the reaction of **2** with isomenthone being contained as an impurity.
12. Considering this NOE experiment, the structures of **D** would be correct because the NOE effect is observed between the 3,5-*cis* protons in the analogous compound previously reported.<sup>13</sup> Mechanism for the formation of **D** from **11a,b** can be considered as follows: **11a,b** was transformed to **11'a,b** by the ring opening followed by prototropy. **11'a,b** was then reduced by LiAlH<sub>4</sub> from less hindered side (lower side) to give the 3,5-*cis* product **D**.



13. DeShong, P.; Dicken, C. M.; Staib, R. R.; Freyer, A. J.; Weinreb, S. M. *J. Org. Chem.* **1982**, *47*, 4397.
14. It is also reported that the nitronone (2-methyl-2-phenyl-3-oxazolin-5-one 3-oxide) obtained from the reaction of acetophenone with **2** reacts with ethyl vinyl ether to give an oxazolidine derivative assigned to be an *endo*-adduct.<sup>6</sup> However, it seems reasonable to assume that the product is the *exo*-adduct.
15. For recent papers dealing with the synthesis of optically active allylglycine, see: (a) Oppolzer, W.; Moretti, R.; Zhou, C. *Helv. Chim. Acta.* **1994**, *77*, 2363; (b) Rose, J. E.; Leeson, P. D.; Gani, D. *J. Chem. Soc. Perkin Trans. 1.* **1995**, 157. In both references, the amino acids were synthesized by the allylation of chiral glycine derivatives in the presence of butyl lithium followed by appropriate manipulations.
16. Dennis, R. L.; Plent, W. J.; Skinner, C. G.; Sutherland, G. L.; Shire, W. *J. Am. Chem. Soc.* **1995**, *77*, 2362.
17. Cramer, V.; Spener, F. *Eur. J. Biochem.* **1977**, *74*, 495.
18. Although several references are available concerning the Lewis acid mediated 1,3-dipolar cycloaddition of nitrones,<sup>19</sup> to the best of our knowledge, the asymmetric cycloaddition involving kinetical resolution of the dipolarophile is hitherto unknown.
19. Recent papers dealing with the 1,3-dipolar cycloaddition of nitrones in the presence of Lewis acid catalyst: (a) Murahashi, S.-I.; Imada, Y.; Kohno, M.; Kawakami, T. *Synlett.* **1993**, 395; (b) Tamura, O.; Yamaguchi, T.; Noe, K.; Sakamoto, M. *Tetrahedron Lett.* **1993**, *34*, 4009. (c) Gothelf, K. V.; Jorgensen, K. A. *J. Org. Chem.* **1994**, *59*, 5687; (d) Kanemasa, S.; Tsuruoka, T.; Yamamoto, H. *Tetrahedron Lett.* **1995**, *36*, 5019; (e) Seerden, J.-P. G.; Kuypers, M. M. M.; Scheeren, H. W. *Tetrahedron: Asymmetry*, **1995**, *6*, 1441.
20. Cramer, V.; Rehfeldt, A. G.; Spener, F. *Biochemistry*, **1980**, *19*, 3074.
21. Williams, R. M.; Sinclair, P.J.; D. Zhai, D.; Chen, D. *J. Am. Chem. Soc.* **1988**, *110*, 1547.
22. Black, S.; Wright, N. G. *J. Biol. Chem.* **1955**, *213*, 39.

(Received in Japan 16 January 1997; accepted 10 March 1997)